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IMPORTANCE Postpericardiotomysyndrome, postoperative atrial fibrillation (AF), andpostop-
erative effusionsmaybe responsible for increasedmorbidity andhealth care costs after cardiac
surgery. Postoperativeuseof colchicineprevented these complications in a single trial.
OBJECTIVE To determine the efficacy and safety of perioperative use of oral colchicine in
reducing postpericardiotomy syndrome, postoperative AF, and postoperative pericardial or
pleural effusions.
DESIGN, SETTING, AND PARTICIPANTS Investigator-initiated, double-blind, placebo-controlled,
randomized clinical trial among 360 consecutive candidates for cardiac surgery enrolled in 11
Italian centers betweenMarch 2012 andMarch 2014. At enrollment, mean age of the trial
participants was 67.5 years (SD, 10.6 years), 69%weremen, and 36% had planned valvular
surgery. Main exclusion criteria were absence of sinus rhythm at enrollment, cardiac
transplantation, and contraindications to colchicine.
INTERVENTIONS Patients were randomized to receive placebo (n=180) or colchicine (0.5 mg
twice daily in patients70 kg or 0.5 mg once daily in patients <70 kg; n=180) starting
between 48 and 72 hours before surgery and continued for 1 month after surgery.
MAINOUTCOMESANDMEASURES Occurrenceofpostpericardiotomysyndromewithin3months;
main secondary studyendpointswerepostoperativeAFandpericardial or pleural effusion.
RESULTS Theprimary endpoint of postpericardiotomysyndromeoccurred in 35patients (19.4%)
assigned to colchicine and in 53 (29.4%)assigned toplacebo (absolutedifference, 10.0%;95%
CI, 1.1%-18.7%;numberneeded to treat = 10). Therewereno significant differencesbetween the
colchicine andplacebogroups for the secondary endpoints of postoperativeAF (colchicine, 61
patients [33.9%]; placebo, 75patients [41.7%]; absolutedifference, 7.8%;95%CI, −2.2%to
17.6%)orpostoperativepericardial/pleural effusion (colchicine, 103patients [57.2%]; placebo,
106patients [58.9%]; absolutedifference, 1.7%;95%CI, −8.5%to 11.7%), although therewas a
reduction inpostoperativeAF in theprespecifiedon-treatment analysis (placebo,61/148patients
[41.2%]; colchicine, 38/141 patients [27.0%]; absolutedifference, 14.2%;95%CI, 3.3%-24.7%).
Adverse events occurred in 21 patients (11.7%) in theplacebogroupvs36 (20.0%) in the
colchicine group (absolutedifference, 8.3%;95%CI;0.76%-15.9%;numberneeded toharm =
12), but discontinuation rateswere similar.No serious adverse eventswereobserved.
CONCLUSIONSANDRELEVANCE Amongpatients undergoing cardiac surgery, perioperativeuse
of colchicine comparedwithplacebo reduced the incidenceof postpericardiotomysyndromebut
not of postoperativeAForpostoperativepericardial/pleural effusion. The increased risk of gastro-
intestinal adverse effects reduced thepotential benefits of colchicine in this setting.
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P ostpericardiotomy syndrome, postoperative atrial fi-brillation (AF), andpostoperativepericardial/pleural ef-fusions are common complications after cardiac sur-
gery, affecting more than one-third of patients, an incidence
largelyunchangeddespiteadvances insurgical techniques, an-
esthetic procedures, and perioperative care.1-6
These complications may have minor effect on manage-
ment (mild fever and effusions) but may also lead to pro-
longed hospital stay, readmissions, and need for invasive in-
terventions; moreover, postoperative AF may increase long-
term mortality.7 Colchicine monotherapy has been recently
suggested to prevent these complications.8-10
Although preliminary data from the Colchicine for Pre-
vention of the Postpericardiotomy Syndrome and Postopera-
tive Atrial Fibrillation (COPPS) trial for 1-month postoperative
treatment with colchicine were promising,10 additional data
will be helpful in determining if colchicine should be used
routinely for the prevention of several relevant perioperative
complications (including postpericardiotomy syndrome,
postoperative AF, and postoperative effusions). Both efficacy
and safety should be evaluated, especially in the periopera-
tive period, preferably with administration of the drug before
cardiac surgery to assess its full beneficial effect in the imme-
diate perioperative period, when most of the studied compli-
cations are more likely to occur. In addition, a limitation of
the COPPS trial was that colchicine was begun on postopera-
tive day 3; whether its beneficial effects may be further opti-
mized when colchicine is started before surgery is uncertain.
Moreover, with preoperative treatment, a loading dose may
be unnecessary; this may further improve adherence, similar
to pericarditis.11-13
We conducted the COPPS-2 trial to determine the effi-
cacy and safety of perioperative administrationof oral colchi-
cine to reduce postpericardiotomy syndrome, postoperative
AF, and postoperative pericardial/pleural effusions.
Methods
Study Design and Patients
TheCOPPS-2 trial isan investigator-initiated,double-blind,pla-
cebo-controlled, randomizedclinical trial conducted in 11 cen-
ters in Italy to test the primary hypothesis that perioperative
use of oral colchicine reduces the occurrence of postpericar-
diotomysyndrome,postoperativeAF, andpostoperativeperi-
cardial/pleural effusions in patients undergoing cardiac sur-
gery for any reasonexcludingcardiac transplantation.Detailed
methods have been previously published11 and are available
in Supplement 1 (trial protocol). The main differences in the
studymethods of theCOPPS andCOPPS-2 trials are described
in the eTable in Supplement 2. The design of the study was
simple and pragmatic to maximize a possible practical appli-
cation that canbe generalized to real-worldpatients. Thedata
were gathered by all authors andwere received, checked, and
analyzed at the CardiologyDepartment ofMaria VittoriaHos-
pital, Torino, Italy, after blinded adjudication of events.
The study was approved by the human subjects commit-
tees of all participating institutions and conducted according
to international standards of good clinical practice. All par-
ticipants provided written informed consent.
Intervention
Patients were randomly assigned to receive placebo or colchi-
cine, starting between 48 and 72 hours before surgery and
continued for 1 month after surgery (Figure 1). Random
assignment to treatment groups was performed by a central
computer–based automated sequence. Randomization was
based on permuted blocks with a block size of 4. The random
allocation sequence was implemented using sequentially
numbered study drug containers. Allocation concealment
was achieved by using opaque sealed envelopes, sequentially
numbered containers, and central randomization. Colchicine
was administered orally as 0.5 mg twice daily to patients
weighing 70 kg or more or as 0.5 mg once daily to patients
weighing less than 70 kg, without a loading dose. Colchicine
was provided by gastric tube in unconscious postoperative
patients. Adherence to study drug therapy was assessed on
the basis of counts of pills in dispensed boxes, with a target of
at least 80% adherence.
The dosing was selected to balance potential efficacy vs
patient intolerance, especially gastrointestinal intolerance.12,13
The duration of colchicine therapy was based on prior stud-
ies suggesting a 1-month length of treatment.8,14
Additionalmedical therapywasprovided according to in-
dividual patient comorbidities and based on existing practice
guidelines.
Centers were encouraged to use continuous electrocar-
diographic (ECG) monitoring for at least 5 days after surgery.
Twelve-lead ECGs were recommended daily and more fre-
quently at the discretion of the treating physicians for symp-
tomsor clinically suspectedarrhythmia.Clinical data andcon-
firmatory ECG strips or 12-lead ECGs were recorded for all
postoperative arrhythmiasof at least 30-secondduration.Cur-
rent best practice guidelines for prevention of postoperative
AF were strongly recommended to all centers.
Figure 1. Screening, Enrollment, Randomization, and Follow-up of Study
Participants in the COPPS-2 Trial
758 Patients undergoing cardiac
surgery assessed for eligibility
398 Excluded
143 Urgent cardiac surgery
108 Atrial fibrillation
86 Declined to participate
61 Other reasons
360 Randomized
180 Included in primary analysis 180 Included in primary analysis
32 Discontinued study 39 Discontinued study
180 Randomized to receive placebo
180 Received allocated intervention
180 Randomized to receive colchicine
180 Received allocated intervention
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End Points
The primary study end point was incidence of postpericardi-
otomysyndromewithin3months. Secondarystudyendpoints
were postoperative AF and postoperative effusions within 3
months after cardiac surgery, incidenceof cardiac tamponade,
needforpericardiocentesisorthoracentesis, recurrencesofpost-
pericardiotomy syndrome, disease-related readmissions (re-
lated to the 3 main outcomes of postpericardiotomy syn-
drome, postoperative AF, and postoperative pericardial/
pleural effusions), stroke incidence, and overall mortality.
The 3-month time frame was selected because almost all
such events in the COPPS trial occurred in the first 3 months
after cardiac surgery.15
Diagnostic criteria for postpericardiotomy syndrome in-
cluded the following (2 of 5 criteria were required for the di-
agnosis): (1) feverwithoutalternativecauses; (2)pleuritic chest
pain; (3) frictionrub;andevidenceofneworworsening (4)peri-
cardialeffusionand/or (5)pleuraleffusionwithevidenceofsys-
temic inflammation by C-reactive protein elevation.11,14,16
Postoperative AFwas defined as AF lasting formore than
30 seconds. Continuous electrocardiographicmonitoringwas
adoptedforat least5daysafter surgery.Twelve-leadECGswere
recommended daily andmore frequently at the discretion of
the treating physicians for symptoms or clinically suspected
arrhythmia. Clinical data (eg, postoperative AF onset time,
symptoms, treatments,andduration)andconfirmatoryrhythm
strips or 12-lead ECGs were collected for all postoperative ar-
rhythmias of at least 30-second duration. Use of long-term or
prophylactic antiarrhythmicdrugs, historyofAF, andplanned
AF ablation were not exclusions, given the similar or higher
risk of postoperative AF in these patients and no known bio-
logical interaction that might reduce the efficacy of colchi-
cine in such patients.11
DataManagement and Safety Evaluation
Data were collected using standardized case report and clini-
cal events forms by investigators who were masked to treat-
mentassignments.Aclinicalendpointcommittee,alsomasked
to treatment, adjudicated all events. During follow-up, all
adverse events were monitored and recorded. Potential ad-
verse eventswere recorded and reported to the steering com-
mittee and a data and safety monitoring committee. An ad-
verse event was considered severe if the event was fatal, was
life-threatening, requiredhospitalization,was significantly or
permanently disabling, or was medically significant (ie, an
event that was life-threatening or required medical or surgi-
cal intervention to prevent an adverse outcome). An adverse
eventwas filed according towhether it was discovered by pa-
tient-reported symptomsor blood chemistrymonitoringdur-
ing follow-upvisits.Unmaskingof the randomizationcodewas
allowed only in the case of a severe adverse event.
Thesteeringcommitteemonitored theprogressof the trial,
and thedataandsafetymonitoringcommitteemonitoredboth
scientific integrity andpatient safety throughout the trial and
could recommend termination or other trial modifications at
any time. After enrollment of 50% of patients, the data and
safetymonitoringcommittee reviewedan interimanalysis and
recommended study continuation.
Follow-up and Covariates
Standardized data were collected on demographics, risk fac-
tors, medical and surgical history, major comorbid condi-
tions,medications,and laboratorymeasures.Postoperative fol-
low-upvisitswere scheduled at 1 day, 3 days, day of discharge
after cardiac surgery, weekly during rehabilitation, 1 month,
and 3 months. Each follow-up visit included physical exami-
nation,bloodchemistry,ECG,echocardiographyaimedat iden-
tification and semiquantitative assessment of pericardial ef-
fusion, and thoracic ultrasound to assess presence of pleural
effusion. At least 1 chest x-ray was performed during cardiac
surgery stay before discharge and then as clinically indi-
cated. Incidence of postoperative AF was assessed by means
of ECG monitoring during intensive care and overall cardiac
surgery stay, ECG at the time of follow-up visits, or sympto-
matic AF recorded by ECG.
Statistical Analysis
All analyseswereprespecifiedprior to closingof the studyda-
tabase. Sample size calculationswere based on previous data
from the COPPS trial.8 Assuming a postpericardiotomy syn-
drome rate of 22% in the placebo group at 3 months and a
2-sided test at the α=.05 level, a total enrollment of 360 pa-
tients was needed to attain a power of 80% to detect a reduc-
tion in the recurrence rate to 11% in the colchicine group. The
study hypothesis was that colchicine would reduce the post-
pericardiotomysyndromerateby50%.Assumingsimilarevent
rates for postoperative AF and postoperative pericardial/
pleural effusions such as in COPPS and the COPPS postopera-
tive AF substudy, the study was adequately powered to as-
sess the effects of colchicine on these outcomes.8-10
Themain analysis was by intention to treat, including all
patients according to treatmentassignedat randomization.An
additional on-treatment analysis was planned based on pa-
tients who were both tolerant of and adherent to colchicine
(includingpatientswithat least80%adherenceover thecourse
of the studyuntil theonset of theprimaryendpoint or theend
of the assigned treatment, whichever occurred first).
The clinical effect of colchicine was further evaluated in
different prespecified subgroups including age (<65 years vs
≥65 years), sex, serum C-reactive protein (nonelevated or el-
evated), and presence or absence of pericardial effusion as-
sessed at 1 to 3 days and at day of discharge after cardiac
surgery.
Quantitative variables are expressed as mean (standard
deviation) or median (range and interquartile range [IQR]) as
appropriate. Qualitative variables are expressed as number
(percentage). Descriptive statistics and χ2 or Fisher exact
tests were performed on dichotomous categorical variables
in both the on-treatment and intention-to-treat analyses.
Outcomes are reported as absolute differences with 95% con-
fidence intervals. Time-to-event distributions were esti-
mated by the Kaplan-Meier method and compared by the
log-rank test. Logistic regression was used to determine odds
ratios (ORs) and 95% confidence intervals for the effect of
treatment in each subgroup. Analyses were performed with
SPSS, version 13.0 (SPSS Inc) and MedCalc, version 12.7.2
(MedCalc Software).
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Results
Study Cohort
Enrollment started in March 2012 and ended in March 2014.
Follow-upcontinuedthroughJune2014,apredeterminedstop-
pingpoint for the completionof follow-up for theprimaryout-
come. Participants were followed up for a median of 95 days
(IQR, 15 days).
Studyenrollment, randomization,andretentionareshown
inFigure 1.Of the758patientswhowere screened, 360 (47.5%)
wereenrolled. Ineligiblepatientsweremostoftenexcludedbe-
cause they required urgent cardiac surgery (36%),were not in
sinus rhythm (27%), or declined consent (22%).
At the end of the enrollment phase, 180 patients were
randomly assigned to each of the 2 treatment groups. No
patients were lost to follow-up and all were analyzed for out-
comes. The baseline demographic and clinical characteristics
of study groups were similar and are reported in Table 1. At
baseline, mean age of the trial participants was 67.5 years (SD,
10.6 years) (median, 70 years; range, 19-89 years), and 248
patients (68.9%) were men. Heart valve surgery was per-
formed in 131 patients (36.4%), coronary artery bypass graft
surgery in 122 patients (33.9%), aorta surgery in 22 patients
(6.1%), andmixed cardiac surgery in 85 patients (23.6%). Peri-
operative medications were similar in the study groups and
included β-blockers in 204 patients (56.7%), angiotensin-
converting enzyme inhibitors or angiotensin-II receptor
blockers in 188 patients (52.2%), and amiodarone in 31
patients (8.6%).
Allpatientswhotolerated treatmentwithcolchicineorpla-
cebo discontinued therapy at 1 month, as planned.
Outcomes
The main outcome results are reported in Table 2. The pri-
mary outcome of postpericardiotomy syndrome occurred in
35 of 180 patients (19.4%) in the colchicine group and in 53 of
180 patients (29.4%) in the placebo group (absolute differ-
ence, 10.0%; 95% CI, 1.1%-18.7%; number needed to treat
[NNT] = 10). The Kaplan-Meier incidence of postpericardi-
otomysyndromebytreatmentgroup is showninFigure2. Post-
operative AF occurred in 61 patients (33.9%) assigned to col-
chicine and in 75 (41.7%) assigned to placebo (absolute
difference, 7.8%; 95%CI, −2.2% to 17.6%); postoperative peri-
cardial/pleural effusions occurred in 103 patients (57.2%) as-
signed tocolchicineand in 106 (58.9%)assigned toplacebo (ab-
solute difference, 1.7%; 95% CI, −8.5% to 11.7%). However, a
reduction of the incidence of postoperative AF was recorded
at theprespecifiedon-treatmentanalysis:postoperativeAFwas
found in 61 (41.2%) of 148 patients assigned to placebo and 38
(27.0%) of 141 assigned to colchicine (absolute difference,
14.2%; 95% CI, 3.3%-24.7%; NNT = 7) because a significant
number of patients experienced gastrointestinal adverse ef-
fects resulting indrugdiscontinuation.MostpostoperativeAF
events occurredbetweenpostoperativedays 1 to 5, peakingon
day 2. Among all 101 episodes, 44 lasted 1 day or less. Two pa-
tients in the placebo group and 2 patients in the colchicine
group were discharged with persistent AF.
No significant differenceswere recorded in other second-
ary end points, including cardiac tamponade, need for peri-
cardiocentesis, thoracentesis, or both, recurrences, postperi-
cardiotomy syndrome and postoperative AF-related
readmissions, stroke, and overall mortality. Effects of colchi-
cineontheprimaryendpointdidnotdiffer significantlyamong
theprespecifiedsubgroups (age<65yearsvsage≥65years, sex,
andpresence/absenceofpericardialeffusion)except in thesub-
group with elevation of elevated serum C-reactive protein
(eFigure in Supplement 2).
Adverse Events
Adverse event rates occurred in 21 patients (11.7%) in the pla-
cebo group and 36 (20.0%) in the colchicine group (absolute
Table 1. Baseline Characteristics of COPPS-2 Participants According to
Treatment Assignmenta
Characteristics
Placebo
(n = 180)
Colchicine
(n = 180)
Age, mean (SD), y 68.0 (10.0) 67.0 (11.1)
Men 115 (63.9) 133 (73.9)
Selected coronary risk factors
Current smoker 54 (30.0) 49 (27.2)
Systemic arterial hypertension 122 (67.8) 121 (67.2)
Diabetes mellitus 42 (23.3) 38 (21.1)
Medical and surgical history
Cardiac surgery 10 (5.6) 10 (5.6)
Pericarditis 1 (0.6) 4 (2.2)
Atrial fibrillation 15 (8.3) 18 (10.0)
Comorbid conditions
COPD 15 (8.3) 15 (8.3)
Hypothyrodism 12 (6.7) 8 (4.4)
Chronic renal failure 13 (7.2) 13 (7.2)
Preoperative pericardial
effusion
2 (1.1) 3 (1.7)
Ejection fraction, mean (SD), % 55.5 (10.1) 55.3 (9.6)
NYHA class
I 42 (23.3) 58 (32.2)
II 109 (60.6) 95 (52.8)
III 26 (14.4) 23 (12.8)
IV 3 (1.7) 4 (2.2)
Perioperative medications
β-Blockers 101 (56.1) 103 (57.2)
Amiodarone 18 (10.0) 13 (7.2)
ACE inhibitors/ARBs 100 (55.6) 88 (48.9)
Other antiarrhytmic drugs 5 (2.8) 4 (2.2)
Cardiac surgery
CABG surgery 59 (32.8) 63 (35.0)
Valvular diseases 69 (38.3) 62 (34.4)
Aortic disease 11 (6.1) 11 (6.1)
Combinedb 41 (22.8) 44 (24.5)
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-II
receptor blockers; CABG, coronary artery bypass graft; COPD, chronic
obstructive pulmonary disease; NYHA, New York Heart Association.
a Data are expressed as No. (%) of participants unless otherwise indicated.
bAny combination of the 3 types of cardiac surgery (CABG, cardiac surgery for
valvular disease, and cardiac surgery aortic disease).
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difference, 8.3%; 95% CI, 0.76%-15.9%; number needed to
harm = 12), primarilybecauseof an increased incidenceof gas-
trointestinal intolerance in 12 patients (6.7%) in the placebo
group and 26 (14.4%) in the colchicine group (absolute differ-
ence, 7.7%;95%CI, 1.4%-14.3%;numberneeded toharm = 13).
Discontinuation rateswere similar at 32patients (17.8%) in the
placebo group and 39 (21.7%) in the colchicine group (abso-
lute difference, 3.9%; 95%CI, −4.4% to 12.5%). No serious ad-
verse events were observed (Table 3).
Discussion
In this multicenter trial, perioperative administration of col-
chicine significantly reduced the incidence of postpericardi-
otomy syndrome after cardiac surgery but did not reduce the
risk of postoperative AF and postoperative pericardial/
pleural effusions by intention-to-treat analysis. Patients re-
ceiving colchicine treatment had more frequent adverse ef-
fects, especially gastrointestinal intolerance generally leading
to study drug discontinuation. About 20% of all patients en-
rolled in the trial discontinued studydrug; this relatively high
rate may have affected the overall efficacy of the drug, espe-
cially for postoperative AF prevention.
Postpericardiotomy syndrome with low-grade fever, of-
ten associated with pericardial/pleural effusion, is relatively
commonafter cardiac surgery, and it is generally related to the
amount of pericardial/pleural manipulation.1,8,14
Different strategies havebeen considered for postpericar-
diotomy syndrome prevention, including aspirin, corticoste-
roids, andcolchicine. Inameta-analysisof894patients,8,14,17,18
colchicine was protective against postpericardiotomy syn-
drome (OR, 0.38; 95% CI, 0.22-0.65), whereas study findings
for methylprednisolone (OR, 1.13; 95% CI, 0.57-2.25) and as-
pirin (OR, 1.00; 95%CI, 0.16-6.11) were negative.19 In a single-
center post hoc analysis of 822 patients who underwent val-
vular surgery and received a single intraoperative dose of 1
mg/kg of dexamethasone or placebo in the DECS trial, corti-
costeroids failed to reduce the incidence of postpericardi-
otomy syndrome (OR, 0.88; 95% CI, 0.63-1.22).20
In the largest trial,COPPS,8360consecutivepatients (mean
age, 66 years; 66%men, n=180 in each treatment group)were
randomized on the third postoperative day to receive either
placebo or colchicine for 1 month (1.0 mg twice daily on the
first day followedby amaintenancedose of 0.5mg twicedaily
in patients weighing ≥70 kg and halved doses for patients
weighing <70 kg). Colchicine significantly reduced the inci-
dence of postpericardiotomy syndrome at 12 months com-
pared with placebo (8.9% vs 21.1%, respectively; P = .002;
NNT=8) and the incidence of postoperative pericardial effu-
sions (relative risk reduction, 43.9%; NNT=10) and pleural ef-
fusions (relative risk reduction, 52.3%; NNT=8).9 The inci-
denceofadverseeffects (primarilygastrointestinal intolerance)
andstudydrugdiscontinuationwas similar between the study
groups, with a nonsignificantly increased rate of both events
in patients receiving colchicine.8,9
InCOPPS-2, colchicinewasgiven48 to72hoursbefore car-
diac surgery to pretreat patients and improve the efficacy of
the drug in the prevention of postoperative systemic inflam-
mation and its complications, especially postpericardiotomy
syndromeandpostoperativeAF.Wealsoavoideda loadingdose
andusedweight-adjusteddoseswith theaimof improvingad-
herence. However, we observed a 2-fold increase of adverse
effects and studydrugdiscontinuations comparedwith those
Figure 2. Results of Kaplan-Meier Analysis of the Primary Outcome
(Incidence of Postpericardiotomy Syndrome)
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Table 2. Primary and Secondary Study Outcomes at 3-Month Follow-up According to Treatment Assignment
Outcomes
No. (%) of Participants
Absolute Difference
(95% CI), %
Placebo
(n = 180)
Colchicine
(n = 180)
Primary end point (postpericardiotomy
syndrome) within 3 mo
53 (29.4) 35 (19.4) 10.0 (1.1 to 18.7)
Main secondary end points
Postoperative atrial fibrillationa 75 (41.7) 61 (33.9) 7.8 (−2.2 to 17.6)
Postoperative pericardial/pleural effusions 106 (58.9) 103 (57.2) 1.7 (−8.5 to 11.7)
Cardiac tamponade 3 (1.7) 1 (0.6) 1.1 (−1.6 to 4.3)
Pericardiocentesis or thoracentesis 13 (7.2) 13 (7.2) 0.0 (−5.6 to 5.6)
Postpericardiotomy syndrome recurrence 3 (1.7) 3 (1.7) 0.0 (−3.3 to 3.3)
Disease-related readmissionsb 2 (1.1) 2 (1.1) 0.0 (−2.7 to 2.7)
Overall mortalityc 2 (1.1) 6 (3.3) 2.2 (−1.6 to 6.1)
Stroke 1 (0.6) 2 (1.1) 0.50 (−2.1 to 3.4)
a Postoperative atrial fibrillation at
the prespecified on-treatment
analysis was recorded in 61 of 148
patients (41.2%) assigned to
placebo and 38 of 141 patients
(27.0%) assigned to colchicine
(absolute difference, 14.2%; 95% CI,
3.3%-24.7%).
bDisease-related readmissions were
those related to postpericardiotomy
syndrome, postoperative atrial
fibrillation, or postoperative
effusions.
c All deaths were in-hospital deaths
related to cardiac surgery and not
related to experimental treatments.
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reported in the COPPS trial, likely due to significant vulner-
ability of patients in the perioperative phase, when the use of
antibiotics andprotonpump inhibitors is commonandalso in-
creases the risk of gastrointestinal adverse effects (eg, diar-
rhea). Nevertheless, efficacy for prevention of postpericardi-
otomy syndrome was maintained, and colchicine was
especially efficacious in the setting of systemic inflammation
with C-reactive protein elevation as suggested by subgroup
analysis. Probably for the same reason, as well as because of
the recording of all postoperative effusions regardless of their
size, hemodynamic importance, and association with sys-
temic inflammation, colchicine failed to prevent all postop-
erative effusions.
Thehigh rateof adverse effects is a reason for concernand
suggests that colchicine should be considered only in well-
selectedpatients. A longer pretreatment timeor initiation 2 to
3 days after surgerymay reduce the occurrence of adverse ef-
fects and improve adherence as reported in the COPPS trial.8
However, the overall prognosis of postpericardiotomy syn-
drome reported in the trial was good; therefore, its preopera-
tive preventionmaybeunnecessary given thehigh rate of ad-
verse effects of colchicine. Early prevention after cardiac
surgery or early specific treatment of the syndrome seems to
warrant better tolerability and similar or better outcomes.8-10
Postoperative AF is themost common complication after
cardiac surgery because of the increasing number of cardiac
surgery operations and the advanced age of the patient popu-
lation. PostoperativeAF increasesmorbidity, length of hospi-
tal stay, and health care costs.5-7
The pathophysiologic basis for the development of post-
operative AF is likely multifactorial, including pericardial in-
flammation, autonomic imbalance in the postoperative pe-
riod, excessive production of catecholamines, and fluid
shifts.21-23 Inflammation, inhomogeneity of atrial conduc-
tion, and incidence of postoperative AF are significantly de-
creased by corticosteroid use,24 suggesting that anti-
inflammatory therapy may be beneficial for its prevention.
Microtubules have a significant role in numerous cellular
cytoskeletal and intracellular transport activities. Colchicine
blocksmicrotubule assembly and can actively disruptmicro-
tubules. Microtubules regulate the localization and interac-
tion of adrenergic receptors and adenylate cyclase and may
modulate the phosphorylation of calcium channels and, as a
result, the response of the atria to autonomic stimulation. Be-
cause autonomic balance is altered in thepostoperative state,
agents that attenuate sympathetic activity (eg, adrenergic re-
ceptor blockers) or the response to sympathetic activity (eg,
colchicine) increase parasympathetic activity,whichmayde-
crease the risk of calcium overload–induced ectopy. In addi-
tion, colchicine attenuates neutrophil activation, endothelial
cell adhesion, andmigration to injured tissues.23 In theCOPPS
postoperative AF substudy, patients receiving colchicine had
a reduced incidence of postoperative AF (relative risk reduc-
tion, 45%; NNT=11) with a shorter in-hospital and rehabilita-
tion stay.10
These experimental and pathophysiologic findings sup-
ported theCOPPS-2 trial hypothesis that colchicine couldpre-
vent postoperativeAF.However, inCOPPS-2, colchicine failed
to reduce the incidence of postoperative AF in the intention-
to-treatanalysis; thehighfrequencyofadverseeffectsanddrug
discontinuation were probably major causes since the pre-
specified on-treatment analysis documented a significant re-
duction of the arrhythmia, indicating that colchicine re-
duced the incidence of postoperative AF in patients who
tolerated the drug. Ongoing studies will better clarify the po-
tentialof thisdrugusing lowerdoses (ie,0.5-0.6mg/d) thatmay
be better tolerated.
Several study limitations should be considered in inter-
preting these findings. We excluded pediatric patients, preg-
nant or lactating women, patients with potential contraindi-
cations or at higher risk of complications following the
administrationof colchicine, andpatientswhohadurgent car-
diac surgery. Thus, the results of COPPS-2 should be properly
interpreted and applied to populations who were eligible for
thestudy.Despiteahighlyselectedpopulation,a relativelyhigh
rate of adverse effects, especially gastrointestinal adverse ef-
fects and drug discontinuation, may limit the clinical appli-
cability of colchicine in perioperative care.While the efficacy
of colchicine for postpericardiotomy syndrome prevention is
confirmed, the extent of efficacy for postoperative AF needs
to be further investigated in future trials. At present, colchi-
cine is not approved for the prevention of postpericardi-
otomy syndrome in North America or Europe, and its use as
such is off label. Moreover, our limited sample size and fol-
low-up might have precluded the identification of rare ad-
verse effects.
Table 3. Adverse Events in COPPS-2 According to Treatment Assignment at 3-Month Follow-up According to Treatment Assignmenta
Adverse Events
No. (%) of Participantsb
Absolute Difference (95% CI), %
Placebo
(n = 180)
Colchicine
(n = 180)
Any adverse events 21 (11.7) 36 (20.0) 8.3 (0.76 to 15.9)
Gastrointestinal intolerancec 12 (6.7) 26 (14.4) 7.7 (1.4 to 14.3)
Hepatotoxicityd 2 (1.1) 1 (0.6) 0.50 (−2.1 to 3.4)
Drug discontinuation 32 (17.8) 39 (21.7) 3.9 (−4.4 to 12.5)
a No serious adverse events (any fatal or life-threatening event requiring
hospitalization or any event that was significantly or permanently disabling
or medically significant; ie, life-threatening or requiring medical or surgical
intervention to prevent an adverse outcome) were reported, as well as
myotoxicity, alopecia, or other adverse effects beyond those reported
in the table.
bData represent the number of affected individuals.
c Diarrhea, nausea, cramping, abdominal pain, or vomiting.
dAny elevation of aminotransferase levels above the normal reference range.
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Conclusions
Among patients undergoing cardiac surgery, periop-
erative use of colchicine compared with placebo reduced
the incidence of postpericardiotomy syndrome but not
of postoperative AF or postoperative pericardial/pleural
effusions. The increased risk of gastrointestinal adverse
effects reduced the potential benefits of colchicine in this
setting.
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